cardiology
DAPT Decision Tool (Ticagrelor vs Clopidogrel)
Guides choice of P2Y12 inhibitor in ACS/PCI. Ticagrelor preferred in high ischaemic risk; clopidogrel preferred in high bleeding risk.
Score interpretation
Clopidogrel preferred
→ Use clopidogrel 75mg OD (loading dose 300-600mg); ticagrelor contraindicated or high bleeding risk
Either acceptable — individualise
→ Discuss with cardiologist; balance ischaemic vs bleeding risk; consider prasugrel if no prior stroke
Ticagrelor preferred
→ Ticagrelor 90mg BD (loading 180mg); superior to clopidogrel in ACS-PCI; check for contraindications
Interpretation bands for the DAPT Choice. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Clopidogrel (Loading Dose) · P2Y12 Inhibitor Antiplatelet — ACS
- Clopidogrel (Elderly) · Antiplatelet — P2Y12 Inhibitor
- Clopidogrel (Stroke/TIA Secondary Prevention) · Antiplatelet (P2Y12 Inhibitor)
- Clopidogrel · Antiplatelet (P2Y12 ADP receptor antagonist)
- Ticagrelor · Antiplatelet (reversible P2Y12 inhibitor)
- Ticagrelor · Antiplatelet
Pathways
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.